Dividend Center Best Dividend Stocks

Best High Yield Dividend Stocks Dividend Aristocrats Dividend Stock Comparison

Dividend Calculator Dividend Returns Comparison Dividend Calendar

My Experts Top Analysts Top Financial Bloggers Top-Performing Corporate Insiders Top Hedge Fund Managers Top Research Firms Top Individual Investors

Personal Finance Center Mortgages Loans Investing & Retirement Spending & Savings

Calculators

401k Retirement Calculator Mortgage Calculator

Compound Interest Calculator Dollar Cost Averaging

Student Loan Calculator Auto Loan Calculator

Education

How To Use TipRanks TipRanks Labs Webinar Center Glossary FAQs

About Us

About TipRanks TipRanks Community Contact Us Careers Reviews Mobile APP

Working with TipRanks

Enterprise Solutions Top Online Brokers Become an Affiliate

Follow Us

News Smart Portfolio Expert Center TipRanksAI

TOOLS

Earnings Calendar

Daily Analyst Ratings

STOCKS

ADVANCED RESEARCH

TipRanks Premium

Invest Like a Pro with Unique Data & Simplifed ToolsTry Now

Dividend Center

Best Dividend Stocks

Best High Yield Dividend Stocks

Dividend Aristocrats

Dividend Stock Comparison

Dividend Calculator

Dividend Returns Comparison

Dividend Calendar

Top Financial Bloggers

Top-Performing Corporate Insiders

Top Hedge Fund Managers

Top Research Firms

Top Individual Investors

Personal Finance Center

Investing & Retirement

Spending & Savings

Calculators

Compound Interest Calculator

Mortgage Calculator

Auto Loan Calculator

Student Loan Calculator

401k Retirement Calculator

Enterprise Solutions

Plans & Pricing

Education

How To Use TipRanks

About Us

TipRanks Community

Working with TipRanks

Enterprise Solutions

Top Online Brokers

Become an Affiliate

Follow Us

PCVX Stock Latest News

Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference

Press ReleasesVaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference

Vaxcyte price target raised to $113 from $69 at Mizuho

PremiumThe Fly

Vaxcyte price target raised to $113 from $69 at Mizuho

1M ago

Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants

PremiumPress Releases

Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants

1M ago

Vaxcyte completes enrollment of Phase 2 study evaluating VAX-24

PremiumThe Fly

Vaxcyte completes enrollment of Phase 2 study evaluating VAX-24

1M ago

Vaxcyte price target raised to $95 from $73 at Needham

PremiumThe Fly

Vaxcyte price target raised to $95 from $73 at Needham

2M ago

Vaxcyte price target raised to $98 from $76 at BTIG

PremiumThe FlyVaxcyte price target raised to $98 from $76 at BTIG

2M ago

Vaxcyte reports Q 4 net loss $180.8M vs $78.1M last year

PremiumThe Fly

Vaxcyte reports Q 4 net loss $180.8M vs $78.1M last year

2M ago

Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

PremiumPress Releases

Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

2M ago

PCVX Upcoming Earnings Report: What to Expect?

PremiumPre-Earnings

PCVX Upcoming Earnings Report: What to Expect?

2M ago

Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

PremiumPress Releases

Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

2M ago

Vaxcyte price target raised to $92 from $80 at BofA

PremiumThe Fly

Vaxcyte price target raised to $92 from $80 at BofA

2M ago

Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

PremiumPress Releases

Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

2M ago

Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

PremiumPress ReleasesVaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

2M ago

Vaxcyte Secures $816.5 Million in Stock and Warrant Sale

PremiumCompany Announcements

Vaxcyte Secures $816.5 Million in Stock and Warrant Sale

3M ago

Vaxcyte Announces Pricing of $750 Million Public Offering

PremiumPress Releases

Vaxcyte Announces Pricing of $750 Million Public Offering

3M ago

Vaxcyte offering $500M in common stock at $64 per share, Bloomberg says

PremiumThe Fly

Vaxcyte offering $500M in common stock at $64 per share, Bloomberg says

3M ago

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

PremiumPress Releases

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

3M ago

Vaxcyte announces common stock, warrants offering, no amount given

PremiumThe Fly

Vaxcyte announces common stock, warrants offering, no amount given

3M ago

Vaxcyte price target raised to $76 from $69 at BTIG

PremiumThe Fly

Vaxcyte price target raised to $76 from $69 at BTIG

3M ago

Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older

PremiumPress ReleasesVaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older

3M ago

Vaxcyte completes enrollment of Phase 1/2 study of VAX-31

PremiumThe Fly

Vaxcyte completes enrollment of Phase 1/2 study of VAX-31

3M ago

Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older

PremiumPress Releases

Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older

3M ago

Trending

S&P 500

Dow Jones

Nasdaq 100

More Trending Stocks >